InnoCare Announces Approval of Phase II Clinical Trial Using

/PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's...

Related Keywords

Guangzhou , Guangdong , China , Hamburg , Germany , Shanghai , Hong Kong , New Jersey , United States , Boston , Massachusetts , Beijing , Nanjing , Jiangsu , Budingen , Rheinland Pfalz , Chinese , Neuroimmunol Neuroinflamm , Jasmine Cui , Chunhua Lu , Prnewswire Innocare Pharma , China National Medical Products Administration , National Reimbursement Drug , Lancet Reg Health West Pac , Care Pharma , Investigational New Drug , Neuromyelitis Optica Spectrum Disorder , Reg Health West Pac , Innocare ,